AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04509258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medicated paraffin oil
Description: refined mixture of liquid hydrocarbons which used as laxative and is suggested to reduce absorption of aluminium phosphide if taken within two hours of administration of the toxin in addition to sodium bicarbonate and ondansetron as standard of care
Study NCT04509258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate Powder and ondansetron
Description: standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
Study NCT04509258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Bicarbonate Powder and ondansetron
Description: standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
Study NCT04210505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Control group will receive standard care as provided by the dialysis center
Study NCT04236973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molbio Truenat™ HCV assay (the investigational product)
Description: The Molbio Truenat™ HCV assay (the investigational product) is a quantitative chip-based Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) tests for the detection of HCV genomic RNA from human whole blood, EDTA plasma and serum. The Truenat™ HCV assay runs on the Truelab™ Uno, Truelab™ Duo or Truelab™ Quadro Dx. Results of testing by Truenat™ HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
Study NCT04236973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abbott RealTime HCV assay
Description: Plasma specimens will be also tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities. Only the results of Abbott RealTime HCV assay may be used to make clinical decisions.
Study NCT00003432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: carcinoembryonic antigen RNA-pulsed DC cancer vaccine
Description: Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses.
Study NCT03389191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Study NCT03411291 — intervention group
Intervention type: DEVICE
Intervention: MRI, MR Spectroscopy, MR Perfusion
Description: One brain MRI/MR Spectroscopy/MR Perfusion at baseline and one brain MR/MR Spectroscopy/MR Perfusion at 3 months.
Study NCT04217850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 250 kcal Dietary Energy Restriction
Description: The nutrition intervention will be individualized and implemented as a free-living energy-restricted eating plan where energy intake will be based on a mild restriction (approx. 250 kcal/day).
Study NCT04217850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Supervised aerobic exercise will be combined with the energy restriction. Individuals will perform aerobic exercise (treadmill, cycle, or rower or combination) 4-5 days per week for 12 weeks. At each session they will expend 250 or more calories to further meet or exceed the 500 kcal energy deficit.
Study NCT00718939 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Rheos Baroreflex Activation Therapy System
Description: The two (2) Rheos Carotid Sinus Leads conduct the activation energy from the Rheos Implantable Pulse Generator to the baroreceptors located on the left (Left Carotid Sinus Lead) and right (Right Carotid Sinus Lead) carotid sinus. This energy activates the baroreflex by inducing signals that the brain interprets as elevated blood pressure.
Study NCT02444598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaccum Assisted Closure device
Description: Negative-pressure wound therapy
Study NCT02444598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional wound dressings
Description: Conventional wound dressings
Study NCT00857545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00857545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polyvalent Antigen-KLH Conjugate Vaccine
Description: Given SC
Study NCT00857545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saponin-based Immunoadjuvant OBI-821
Description: Given SC
Study NCT03207672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389-LF
Description: intravenous infusion
Study NCT03929770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: with pause
Description: When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner pause the advancement for 10 sec. Next, the practitioner re-advance it to the pulmonary artery.
Study NCT03929770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: without pause
Description: When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner advance it continuously without pause to the pulmonary artery.
Study NCT03071653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left Cardiac Sympathetic Denervation (LCSD)
Description: The procedure involves the surgical removal of the lower half of the left stellate ganglion (T1) and thoracic ganglia (T2-T4), thereby removing the pro-arrhythmic noradrenergic input to the ventricles
Study NCT03071653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Description: All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include:~1. A renin angiotensin system blocker at highest tolerated doses (e.g., enalapril 10mg twice daily or equivalent)~2. A mineralocorticoid receptor antagonist (e.g., Spironolactone 25-50mg daily or equivalent)~3. A Beta-blocker (e.g., Carvedilol 25mg twice daily or equivalent)~4. The use of a loop diuretic and digitalis will be clinically driven and used at the discretion of the attending clinician
Study NCT03071653 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Optimal Medical Therapy
Description: All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include:~1. A renin angiotensin system blocker at highest tolerated doses (e.g., enalapril 10mg twice daily or equivalent)~2. A mineralocorticoid receptor antagonist (e.g., Spironolactone 25-50mg daily or equivalent)~3. A Beta-blocker (e.g., Carvedilol 25mg twice daily or equivalent)~4. The use of a loop diuretic and digitalis will be clinically driven and used at the discretion of the attending clinician
Study NCT01512810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
Study NCT03216538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AS101 1% oral solution
Description: 0.4 ml daily p.o.
Study NCT03425955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUNEKOS ® 200
Description: 4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days. Two different injection techniques were carried out mono-laterally on the left or right face side randomly: interstitial fluid technique (IFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side.
Study NCT03900806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online cognitive rehabilitation
Description: The cognitive rehabilitation program will be based on the protocol of a frequently used meta-cognitive strategy approach applied in many rehabilitation centers in the Netherlands. The program consists of several modules that can be used in a flexible way, depending on the specific individual problems and goals. Therapists have undergone additional training in issues related to cancer-related cognitive impairment and problems occupationally active cancer survivors might experience at work. In both intervention arms, participants will receive access to a secured personal webpage, where all content relevant to the treatment sessions can be obtained.
Study NCT03425955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUNEKOS® 1200 and SUNEKOS® 200
Description: 5 micro-injection sessions (one of the product SUNEKOS® 1200 and four of SUNEKOS® 200. SUNEKOS® 1200 was injected bi-laterally on the face with cushion technique. 24 hours after the SUNEKOS® 1200 treatment, 4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days were performed . SUNEKOS® 200 was injected with two different techniques, carried out mono-laterally on the left or right face side randomly: retrograde interstitial fluid technique (RIFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side.
Study NCT01728103 — intervention group
Intervention type: DEVICE
Intervention: APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays
Description: In Vitro Diagnostic Assays
Study NCT02431156 — intervention group
Intervention type: OTHER
Intervention: Assessment of visual capacity
Description: Visual capacity (VC) is variable comprised by three sub-variables: a) (DVC) Visual capacity for activities requiring distant vision, b) (IVC) Visual capacity for activities requiring intermediate vision, and c) (NVC) Visual capacity for activities requiring near vision.~VC will be measured in a scale from 1 to 100 as the sum of the DVC, IVC and NVC
Study NCT03216538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.4 ml daily p.o.
Study NCT02074488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balancing Act exercise curriculum
Description: Balance improvement exercise curriculum titled Balancing Act
Study NCT04482699 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RAPA-501-Allo off-the-shelf Therapy of COVID-19
Description: Allogeneic off-the-shelf RAPA-501 cells
Study NCT02074488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Brochure
Description: Informational Brochure on falls prevention
Study NCT02074488 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Informational Brochure
Description: Informational Brochure on falls prevention
Study NCT03875365 — intervention group
Intervention type: PROCEDURE
Intervention: POPE
Description: Patients who have undergone Per-oral Plication of the Esophagus (POPE) procedure.
Study NCT04286750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1004-1239
Description: ACT-1004-1239 administered as hard capsules for oral use.
Study NCT05732181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The skin lidocaine patch.
Description: The skin patch is applied before RFA while admission and is changed every day till discharge. Pain severity is evaluated by visual analogue scale using a 10-point scale recorded before RFA and after the procedure.
Study NCT05732181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: patch without drugs
Study NCT02860182 — intervention group
Intervention type: OTHER
Intervention: measure the elastic properties of aortic wall
Study NCT04286750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered as hard capsules for oral use.
Study NCT05276037 — intervention group
Intervention type: OTHER
Intervention: Liver transplantation
Description: Both groups will receive the same advantages on the LT waiting list (SE points)
Study NCT03984045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical
Description: Intranasal 2% lidocaine delivered directly to SPG
Study NCT03984045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochlorperazine Injection
Description: intravenous prochlorperazine at 0.15mg/kg max 10 mg
Study NCT02680418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Study NCT01940419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 1g Tranexamic acid iv administered over 10 minutes just before surgery
Study NCT01940419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 ml sodium chloride iv administered over 10 minutes just before surgery
Study NCT02951260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 17 days treatment with metformin
Study NCT02951260 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 17 days treatment with placebo
Study NCT03601299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional food
Description: Increasing traditional food consumption through Head start programs in Alaska
Study NCT04482699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RAPA-501-Allo off-the-shelf Therapy of COVID-19
Description: Allogeneic off-the-shelf RAPA-501 cells
Study NCT04482699 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: RAPA-501-Allo cell placebo
Study NCT04662242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium Supplement
Description: Zelnite 400mcg/day in normal saline 100ml iv infusion for 7 days
Study NCT04662242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selenium Supplement
Description: Zelnite 400mcg/day in normal saline 100ml iv infusion for 7 days
Study NCT04662242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline 100ml iv infusion for 7 days
Study NCT02803684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI examination with tensor diffusion protocol acquisition. No injection needed.
Description: standard MRI examination
Study NCT03986957 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: No interventions - observational study
Study NCT02525679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655130 (spesolimab)
Study NCT02525679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02629861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration.~The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site.
Study NCT04003077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser meridian massage
Description: The participants will undergo 12 sessions of laser meridian massage, thrice a week, for 4 weeks, using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.5cm\^2; power density, 300mW/cm\^2; pulsed wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The laser treatment will be applied to the back including Bladder meridian (BL11-25) and Governor vessel (GV3-14) for 15 minutes, to deliver a total treatment dose of 67.5J/cm\^2.
Study NCT01566643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RA5-RACM7
Description: rabeprazole 20mg bid + amoxicillin 1g bid treated for 5 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
Study NCT01566643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RA3-RACM7
Description: rabeprazole 20mg bid + amoxicillin 1g bid treated for 3 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
Study NCT02629861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
Study NCT02629861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
Study NCT03888560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations
Description: MOPs will be performed using SIA Excalibur Mini-Implant with dimension 1.6 mm in width and length of 6 mm, screw 3 mm depth into buccal bone of intervention sites
Study NCT03366337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl capsules
Description: Bardoxolone 5 mg capsules
Study NCT01479478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo capsule daily.
Study NCT01479478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic dietary supplement
Description: Dietary Supplement: Lactobacillus rhamnosus GR-1, Lactobacillus reuteri RC -14
Study NCT01142271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Billroth-I
Description: Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, gastroduodenostomy should be performed by circular stapler. In addition, stapler sites were re-enforced.
Study NCT01142271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux en Y
Description: Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, jejunojejunostomy and gastrojejunostomy should be performed by circular staplers. In addition, stapler sites were re-enforced.
Study NCT01566643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RA7-RACM7
Description: rabeprazole 20mg bid + amoxicillin 1g bid treated for 7 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
Study NCT01593163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen EchoG
Description: Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
Study NCT01593163 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard ibuprofen treatment
Description: Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
Study NCT03247205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HipERS
Description: This is a graduated, functionally-based exercise intervention conducted in the participant's home. The intervention incorporates verbal encouragement and positive reinforcement, role modeling, assessment of and elimination of unpleasant sensations associated with an activity, and confidence building through activity repetition. The exercise component includes 1) strengthening exercises, 2) range of motion exercises, 3) balance training, 4) functional training, such as chair rising, ambulation training, and stair climbing, 5) transfer practice, 6) adjusting walking aides, and 7) adapting and modifying environment; with a focus on lower extremity tasks in all these areas.
Study NCT04203654 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cognitive-behavior group therapy
Description: cognitive-behavior group therapy Frequency: thrice a week Treatment duration: 16 week
Study NCT04203654 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individual supportive psychotherapy
Description: Individual supportive psychotherapy 3 sessions during the 16-week treatment period
Study NCT04496700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole blood donation and transfusion
Description: The effect of whole blood donation on physical performance:~Donation of 450 ml whole blood - one time only.
Study NCT02704676 — intervention group
Intervention type: OTHER
Intervention: marker(CA-125)
Description: measuring CA-125 in pregnant women (normal,mild and sever pre-eclampsia)
Study NCT04257955 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview and evaluation of Engagement
Description: (i) the completion of the scheduled outpatients visit (ii) filling of the PHE-Scale® questionnaire by the patient to investigate the level of engagement and (iii) the completion of a semi-structured interview to assess the rate of understanding of the information received from the doctor.
Study NCT04182698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simultaneous chemoradiotherapy for An Luo
Description: Experimental group: anlotinib(d1-14, d22-36), followed by 21 days period, 2 weeks medication, 1 week maintenance therapy.~. Group II: 10 mg po qd, Group III: 12 mg po qd;~Combined chemotherapy:~Cisplatin + etoposide Or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + cultured beauty (non squamous cell carcinoma). Synchrotron radiation: radiotherapy combined with radiotherapy (3D-CRT or IMRT) (60-66Gy / day).~The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD.
Study NCT01783717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks